Integra LifeSciences (NASDAQ:IART) Updates FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.410-2.510 for the period, compared to the consensus earnings per share estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its FY25 guidance to $2.41 to $2.51 EPS.

Wall Street Analysts Forecast Growth

IART has been the topic of several analyst reports. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target on the stock. Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Trading Up 0.7 %

IART traded up $0.15 during mid-day trading on Friday, hitting $23.21. 698,610 shares of the stock were exchanged, compared to its average volume of 618,446. The firm's fifty day moving average is $23.77 and its two-hundred day moving average is $21.85. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $40.92. The company has a market cap of $1.79 billion, a PE ratio of -257.86, a PEG ratio of 0.73 and a beta of 1.17. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same quarter last year, the firm posted $0.89 earnings per share. The business's revenue for the quarter was up 11.5% compared to the same quarter last year. Equities analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.10% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.